Rating Rationale
June 10, 2020 | Mumbai
Tirupati Wellness LLP
Rating continues on 'Watch Positive'
 
Rating Action
Total Bank Loan Facilities Rated Rs.35 Crore
Long Term Rating CRISIL BB (Continues on 'Rating Watch with Positive Implications')
1 crore = 10 million
Refer to annexure for Details of Instruments & Bank Facilities
Detailed Rationale

CRISIL rating on the long-term bank facilities of Tirupati Wellness LLP (TW; part of the Tirupati group) continue to be on 'Rating Watch with Positive Implications'.
 
CRISIL on Mar 16, 2020 had continued the rating on watch with positive implications, owing to limited information and understanding about the merger process.
 
CRISIL is in discussion with the management, and will take a final rating action once there is clarity on the overall impact on the company's business and financial risk profiles.
 
The rating continues to reflect established relationship with customers and comfortable financial risk profile. These strengths are partially offset by susceptibility to fluctuations in raw material prices, industry competition, and regulatory risks; and large working capital requirement.

Analytical Approach

To arrive at its rating, CRISIL has combined the business and financial risk profiles of TML, Tirupati Lifesciences (TL), and TW. This is because all these entities, together referred to as the Tirupati group, are in the same business, and share common promoters and top management. They are also likely to support each other in case of any exigency.

Please refer Annexure - List of entities consolidated, which captures the list of entities considered and their analytical treatment of consolidation.

Key Rating Drivers & Detailed Description
Strengths: 
* Established relationship with customers: The group's strong track record and healthy relationship with customers have enabled it to diversify product profile to over 1,000 products, with about 100 types of generic formulations. It has over 100 active customers, including renowned players in the Indian pharmaceutical sector. The benefits from the same will continue to aid the business risk profile over the medium term.
 
* Comfortable financial risk profile: Net worth was healthy at Rs 135.5 crore as on March 31, 2019, despite sizeable withdrawals in the past. This led to comfortable gearing of 1 time. Debt protection metrics were strong, as reflected in net cash accrual to adjusted debt and interest coverage ratios of 0.2 time and 5.9 times, respectively, for fiscal 2019. Financial risk profile is expected to remain steady over the medium term because of nil debt-funded capital expenditure.
 
Weaknesses:
* Large working capital requirement: Gross current assets (GCAs) were estimated at around 122 days as on March 31, 2019, because of receivables of 71 days and inventory of around 50 days. Working capital requirement is funded through moderate credit from domestic suppliers, internal accrual, and bank borrowings. Operations are expected to remain working capital intensive over the medium term.
 
* Susceptibility to fluctuations in raw material prices, industry competition, and regulatory risks: Raw materials comprise solvents or basic chemicals, and crude-based derivatives. Although there is a pass-through mechanism for any adverse fluctuation in input prices, the group's bargaining power with customers is restricted by intense competition. Any change in government policy can also have a major impact on business risk profile.
Liquidity Adequate

Accrual is likely to remain over 2-2.5 times that of maturing debt, and is expected to be in the range of Rs 50-60 crore per annum in fiscals 2020 and 2021. Bank limit (of Rs 72 crore) utilisation averaged 95% for the 12 months ended April 2019. Current ratio was weak at 0.95 time as on March 31, 2019.

Rating Sensitivity factors
Upward factors
* Sustained revenue growth and maintenance of operating profitability at over 13%
* Better accruals and improvement in working capital cycle, leading to moderation in bank limit utilization
 
Downward factors
* Decline in revenue or profitability
* Stretched working capital cycle, with GCAs escalating to beyond 150 days
* Weakening of capital structure, with total outside liabilities to tangible net worth ratio exceeding beyond 2 times
About the Group

TML is a closely held public limited company that undertakes contract manufacturing of generic pharmaceutical formulations. Products include laxatives, pain killers, analgesic, and anti-diabetic formulations. Facility is in Sirmour, Himachal Pradesh.
 
Established in 2010, TL manufactures protein supplements and nutraceutical products. Operations are managed by its promoters, Mr Ashok Goyal, Mr Dinesh Goyal, Mr Arun Goel, and Mr Ajay Goel.
 
TW (formerly, Ubesha Engineering) was set up in 2010 and was taken over by the Tirupati group in 2013. The unit started operations at rented premises in Gondpur Industrial Area in Himachal Pradesh, and later shifted operations to Village Surajpur in Chhattisgarh. The firm manufactures empty tins and PTI caps. TW has also set up a unit to manufacture protein powder (health supplements).

Key Financial Indicators
Particulars Unit 2019 2018
Revenue Rs crore 77.26 46.86
Profit after tax Rs crore 0.1 0.01
PAT margin % 0.1 0.02
Adjusted debt/adjusted net worth Times 1.68 3.59
Interest coverage Times 2.9 1.0

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments. The CRISIL complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.
Annexure - Details of Instrument(s)
ISIN Name of instrument Date of
allotment
Coupon
rate (%)
Maturity
date
Issue size
(Rs crore)
Rating assigned
with outlook
NA Cash Credit NA NA NA 12 CRISIL BB/Watch Positive
NA Term Loan NA NA Oct-23 23 CRISIL BB/Watch Positive
 
Annexure - List of entities consolidated
Names of entities consolidated Extent of consolidation Rationale for consolidation
Tirupati Medicare Ltd Full Common management and engaged in the same business
Tirupati Lifesciences Full Common management and engaged in the same business
Tirupati Wellness LLP Full Common management and engaged in the same business
Annexure - Rating History for last 3 Years
  Current 2020 (History) 2019  2018  2017  Start of 2017
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund-based Bank Facilities  LT/ST  35.00  CRISIL BB/(Watch) Positive  16-03-20  CRISIL BB/Watch Positive  24-12-19  CRISIL BB/Watch Positive  02-05-18  CRISIL BB/Stable  16-10-17  CRISIL B/Stable (Issuer Not Cooperating)*  CRISIL B/Stable 
            30-09-19  CRISIL BB/Watch Positive  25-04-18  CRISIL BB/Stable       
            07-01-19  CRISIL BB/Stable           
All amounts are in Rs.Cr.
*Issuer did not cooperate; based on best-available information
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Cash Credit 12 CRISIL BB/Watch Positive Cash Credit 12 CRISIL BB/Watch Positive
Term Loan 23 CRISIL BB/Watch Positive  Term Loan 23 CRISIL BB/Watch Positive
Total 35 -- Total 35 --
Links to related criteria
CRISILs Approach to Financial Ratios
Framework for Assessing Information Adequacy Risk
Rating criteria for manufaturing and service sector companies
CRISILs Criteria for Consolidation
Criteria for rating entities belonging to homogenous groups

For further information contact:
Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
naireen.ahmed@crisil.com

Nitin Kansal
Director - CRISIL Ratings
CRISIL Limited
D:+91 124 672 2154
nitin.kansal@crisil.com


Gaurav Arora
Rating Analyst - CRISIL Ratings
CRISIL Limited
D:+91 124 672 2181
Gaurav.Arora@crisil.com


Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a leading agile and innovative, global analytics company driven by its mission of making markets function better. We are India’s foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 1,00,000 customers.
 
We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.
 
For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK

About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 1,10,000 MSMEs have been rated by us.


CRISIL PRIVACY
 
CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL.For further information on CRISIL’s privacy policy please visit www.crisil.com.


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.CRISIL or its associates may have other commercial transactions with the company/entity.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL